|
|
| Record Information |
| Record ID |
19 |
| Pubmed ID |
28451790 |
| SNP |
|
| Gene ID |
1493 |
| Protein ID |
P16410 |
| Vaccine Adverse Events |
usual type vulvar intraepithelial neoplasia |
| Vaccine |
HPV16 E7 DNA vaccine |
| Gene Name |
CTLA4 |
| Official Symbol |
cytotoxic T-lymphocyte associated protein 4 [Homo sapiens (human)] |
| Aliases |
ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 |
| Other Designations |
cytotoxic T-lymphocyte protein 4; celiac disease 3; cytotoxic T lymphocyte associated antigen 4 short spliced form; cytotoxic T-lymphocyte-associated serine esterase-4; insulin-dependent diabetes mellitus 12; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4 |
| Chromosome |
2 |
| Location |
2q33.2 |
| Annotation |
Chromosome 2 NC_000002.12 (203867771..203873965) |
| MIM |
123890 |
| DNA Sequence |
>NC_000002.12:203867771-203873965 Homo sapiens chromosome 2, GRCh38.p14 Primary Assembly
GCTTTCTATTCAAGTGCCTTCTGTGTGTGCACATGTGTAATACATATCTGGGATCAAAGCTATCTATATA
AAGTCCTTGATTCTGTGTGGGTTCAAACACATTTCAAAGCTTCAGGATCCTGAAAGGTTTTGCTCTACTT
CCTGAAGACCTGAACACCGCTCCCATAAAGCCATGGCTTGCCTTGGATTTCAGCGGCACAAGGCTCAGCT
GAACCTGGCTACCAGGACCTGGCCCTGCACTCTCCTGTTTTTTCTTCTCTTCATCCCTGTCTTCTGCAAA
GGTGAGTGAGACTTTTGGAGCATGAAGATGGAGGAGGTGTTTCTCCTACCTGGGTTTCATTTGTTTCAGC
AGTCAAAGGCAGTGATTTATAGCAAAGCCAGAAGTTAAAGGTAAAACTCCAATCTGGCTTGGCTGGCTCT
GTATTCCAGGGCCAGCAGGGAGCAGTTGGGCGGCAGCAAATAAGGCAAAGAGATAGCTCAGAACAGAGCG
CCAGGTATTTAGTAGGGGCTTCATGAATGCATGTGAGTTGGTTTAGTAGAGAGACACAGGCAATTTCAGA
CCCTTCTATGAGACTGGAAGTGATTTAAGAGGGAAAGGATAGCCATAGTCCTGAATACATTTGAGCTGGG
TTTCAGGATGAGCTCACAAGTTCCTTTAAAAAAAATTGACTTAAGCAAATCCTGGGAAGAGTTTTTTTGC
TATACAATTCAAGGTTTTAAGGTCCTCGGATTCATATACTTTATAAATGAATTAGCCAGCTTGTTTAAAA
TGTAGGGAAATTGTGGGAAGAATGCCTTCTTTACTTAATTCAAGGTTTTAAGGTTCTCTTAATCAATTCT
ACTAGCTAATTAGCCAATTATTTAAAAATAAAAGTTTGAAATTGCCAAAAAAAAAAGACAAGGAAAAGGA
AAGAAAGAAAGCCACCAGTCTGTTTGGCATACAATACTTAATTGTTGCCTGACCTACGTGTGGGTTTCAG
ATGCAGATCCTCAGTTTTCAGCTCTTCAGAGACTGACACCAGGTTTGTTACACGGCTTAAAATGATGAGT
ATATCCATTGAATCTCAACCTTATCTCTCTCTAGACCTTCTTGGTTAAGAAACCATGTAGTTTGTATGAA
GTAGGTACTCAAAAGATATTTGATGATTTAATTTTTACTGGAGAAGAAATATTCATATATGTTTTCTTAT
TTTTACATGTTTTAAATATGTAAAGATTAAATAAACACTCTTAGAAGTATTTAAATTTCCTAAAGTAAAT
TTATCTCAACCAGTAACAGGACCCTCCCAATACTGGAAAGTTGAGTGTGACCGCATTTAGTGGTGATGAG
TGTGAGCTTGCTTGGGGAGAGGGCAGGACATTTAGGATTTCTTAAGCTTAGAGTCAATACAATAAAGATT
ATTGAGTGCTCACTTGGGTGGGCTATAATCACTGCTCACAGGAGTTCATGAACCACAAGTAAAAGAGTGA
GGAGATATGATTAGCTCACAAATAACTTTAATACAGAGCAGAAAGTAATGAACTACTGCAATGGAGTTAT
CACAGTGCTAAGGATGCTCAGAGGGCATCTCTGATAGGCAGAGGTGAGGGTTAGGGAAGGAAGCTGTAGT
CTAGCTAGCTAGAGCTGCTGGAATAGACATGACAATGGCTGCTGCCAAACTGTTTTCTCTTCTGAGGACA
GATGTCCCGTGCAAGTGGCTTGGTGGAAGGGACTAGTGTCTCTAATATAGGGTGATTTATAAGCAGGAAA
GTGTGTCCTAGAAATTCAGACCAGAGTGATAGATTGGAATTGGATCATGGGGGACTCATTGAATGTTATT
TATTGTATTTGTTTTTGCGATCAGTGTTAGTAAAGTGTCAAAGGGATTGAGCAGATGAGTGACATCATGC
AACACAAGTTTTGAGTTTCACTTGTCAGACTGACTGGAGAGGGGCCTGGTTAGTTACAGGAAGGTAATTT
GGCATGCAGCCACTATTTTTGAGTTGATGCAAGCCTCTCTGTATGGAGAGCTGGTCTCCTTTATCCTGTG
GGAAAAGAGAACAAAGGAGCATGGGAGTGTTCAAGGGAAGGAGAAATAAAGGGCAGAGAGGCAGCGGTGG
TGTCAGGGGAAGCCCACAGGAGTTAACAGCAGGGTTGCCTCAACCTAGAGAGGAAGCGACCTGGTGCCCT
CGGCTCTGTGGCTTCCTTCATCTAACAACATCTTCCACTCTACAACAATGCCAGGGAAGGCGGAGGCTGG
TACAGTGCATCAAGACACAGCTACTCCTGGGTGACAGAGGTTCAGGGCCAGCTCACTAAGTAGGCAGAAG
TTTTTGACATATACTTTGAGAGATAAAGCAAGATTCTGTACCTCAACCTTCAGAATTTCCCCTACCACTC
ATTATAGTTCCGGAGCTATATAGCTCCTATCATTCTATCATAACCTTAGAATACCAGAGAACATATCATC
TCATCTAATTATCTCTTACTATATGTGAAAAAAATGAAGGACATGGGGGAAGTGTGACTTGCCCCAAATC
ACATATTTCATGGTAGAGCCAGGTCTTCTGTTTGTCATATCAGTGTTCTTCCTGCCACAACCATCTTGAA
GAATCTATTTCTCAGTAAGAAAATATCTTTATGGAGAGTAGCTGGAAAACAGTTGAGAGATGGAGGGGAG
GCTGGGGGTGTGGAGAGGGGAAGGGGTAAGTGATAGATTCGTTGAAGGGGGGAGAAAAGGCCGTGGGGAT
GAAGCTAGAAGGCAGAAGGGCTTGCCTGGGCTTGGCCATGAAGGAGCATGAGTTCACTGAGTTCCCTTTG
GCTTTTCCATGCTAGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGAGGCATCGCCAG
CTTTGTGTGTGAGTATGCATCTCCAGGCAAAGCCACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGAC
AGCCAGGTGACTGAAGTCTGTGCGGCAACCTACATGATGGGGAATGAGTTGACCTTCCTAGATGATTCCA
TCTGCACGGGCACCTCCAGTGGAAATCAAGTGAACCTCACTATCCAAGGACTGAGGGCCATGGACACGGG
ACTCTACATCTGCAAGGTGGAGCTCATGTACCCACCGCCATACTACCTGGGCATAGGCAACGGAACCCAG
ATTTATGTAATTGGTGAGCAAAGCCATTTCACTGAGTTGACACCTGTTGCATTGCAGTCTTCTATGCACA
AAAACAGTTTTGTTCCTTAATTTCAGGAGGTTTACTTTTAGGACTGTGGACATTCTCTTTAAGAGTTCTG
TACCACATGGTAGCCTTGCTTATTGTGGGTGGCAACCTTAATAGCATTCTGACTGTAAAATAAAATGATT
TGGGGAAGTTGGGGCTCTCGCTCTGGAGTGCTAACCATCATGACGTTTGATCTGTACTTTTGATATGATA
TGATGCTCCTGGGGAAGTAGTCCCAAATAGCCAAACCTATTGGTGGGCTACCCATGCAATTTAGGGGTGG
ACCTCAAGGCCTGGAAGCTCTAATGTCCTTTTTTCACCAATGTTGGGGAGTAGAGCCCTAGAGTTTAAAA
CTGTCTCAGGGAGGCTCTGCTTTGTTTTCTGTTGCAGATCCAGAACCGTGCCCAGATTCTGACTTCCTCC
TCTGGATCCTTGCAGCAGTTAGTTCGGGGTTGTTTTTTTATAGCTTTCTCCTCACAGCTGTTTCTTTGAG
CAAAATGGTGAGTGTGGTGCTGATGGTGCACCATGTCTGATGGGGATACCTTTAGTGGTATCAACTGGCC
AAAAGATGATGTTGAGTTTAGTGTTCTTGAGATGAGATGAGGCAATAAATGAAGAGGAAGGACAGTGGTA
AAGAACGCACTAGAACCGTAGGCATTGGCATTTGAGGTTTCAGAATGACTAATATTTTAGATGAATTTGT
TTGACATTGAATGTTCATGTGCTTCTGAGCAGGGTTTCAATTTGAGTAACCGTTGCAATAACATGGGGCA
GCTGTTTTGCTCTTTGTCTTCATGACAACTGTACTTAAGCTAACAGCCCTGAAACATGAGATTAGGCTGG
GCAGAATGCTGCTAGAGAGGACCACTTGGATGGTCTTTATTCTCCTTCTCCATGTCCCTCTCCATCACCT
GGAAGTCACCTCTGGGTGCCACTCTGGTGCCTTCCTTGTCGAAGCTGTAGCTGCTCACATGACACCTATC
CCTGTTATCCAGTTTGCTTGACTGGGACGTTTTGCCTTCCCCTTCAGCCAGGAAGTGAAAGTCCCAGTTT
TTATTTATCACAGGTGTTGGTATTGGTGGTAGAAGAGGTAGAATTATGGAATCAGGCCTCCTGTCAGGAT
TTCTTTTTGACAGTCCCTCTCAGACACCTCTGCCTAAGGCCAGCTTTGCCATTACAAACTCTCCCTTCTC
CCTCTCTCCCTTCTTCTCTTCCTCTTCCTTCTTCTCGCTCTTTCTCTCTCTCTCTTTCTCCCTCTCTGTC
TCTTATACACATACACAAAGATATACTCTATTCCAACATCCTCTACCCAACCTGACAGAGATGTCCTTTG
CTGTAGGTTCAGCAGTGGGGATGAGAAATACAGCTCTCAAACAGGATAACTAAAGCTTATTATCTTATCA
AGCTTGTTCCCTTGCAGACAAGATTGATCAATTATCATAGGCTTTCTGGGTGTTCTTTCTGAAGCTTTCT
CAAAGTCTCTTTCTCCTATCTTCCATTCAAGGCAAATGATTGCCATTTAACATCAAAATCACAGTTATTT
ATCTAAAATAAATTTTAATAGCTGAATCAAGAAAATCTCCTGAGGTTTATAATTCTGTATGCTGTGAACA
TTCATTTTTAACCAGCTAGGGACCCAATATGTGTTGAGTTCTATTATGGTTAGAAGTGGCTTCCGTATTC
CTCAGTAGTAATTACTGTTTCTTTTTGTGTTTGACAGCTAAAGAAAAGAAGCCCTCTTACAACAGGGGTC
TATGTGAAAATGCCCCCAACAGAGCCAGAATGTGAAAAGCAATTTCAGCCTTATTTTATTCCCATCAATT
GAGAAACCATTATGAAGAAGAGAGTCCATATTTCAATTTCCAAGAGCTGAGGCAATTCTAACTTTTTTGC
TATCCAGCTATTTTTATTTGTTTGTGCATTTGGGGGGAATTCATCTCTCTTTAATATAAAGTTGGATGCG
GAACCCAAATTACGTGTACTACAATTTAAAGCAAAGGAGTAGAAAGACAGAGCTGGGATGTTTCTGTCAC
ATCAGCTCCACTTTCAGTGAAAGCATCACTTGGGATTAATATGGGGATGCAGCATTATGATGTGGGTCAA
GGAATTAAGTTAGGGAATGGCACAGCCCAAAGAAGGAAAAGGCAGGGAGCGAGGGAGAAGACTATATTGT
ACACACCTTATATTTACGTATGAGACGTTTATAGCCGAAATGATCTTTTCAAGTTAAATTTTATGCCTTT
TATTTCTTAAACAAATGTATGATTACATCAAGGCTTCAAAAATACTCACATGGCTATGTTTTAGCCAGTG
ATGCTAAAGGTTGTATTGCATATATACATATATATATATATATATATATATATATATATATATATATATA
TATATATATATATTTTAATTTGATAGTATTGTGCATAGAGCCACGTATGTTTTTGTGTATTTGTTAATGG
TTTGAATATAAACACTATATGGCAGTGTCTTTCCACCTTGGGTCCCAGGGAAGTTTTGTGGAGGAGCTCA
GGACACTAATACACCAGGTAGAACACAAGGTCATTTGCTAACTAGCTTGGAAACTGGATGAGGTCATAGC
AGTGCTTGATTGCGTGGAATTGTGCTGAGTTGGTGTTGACATGTGCTTTGGGGCTTTTACACCAGTTCCT
TTCAATGGTTTGCAAGGAAGCCACAGCTGGTGGTATCTGAGTTGACTTGACAGAACACTGTCTTGAAGAC
AATGGCTTACTCCAGGAGACCCACAGGTATGACCTTCTAGGAAGCTCCAGTTCGATGGGCCCAATTCTTA
CAAACATGTGGTTAATGCCATGGACAGAAGAAGGCAGCAGGTGGCAGAATGGGGTGCATGAAGGTTTCTG
AAAATTAACACTGCTTGTGTTTTTAACTCAATATTTTCCATGAAAATGCAACAACATGTATAATATTTTT
AATTAAATAAAAATCTGTGGTGGTCGTTTTCCGGA
|
| Protein Name |
CTLA4_HUMAN |
| Length |
223 |
| Moltype |
AA |
| Topology |
linear |
| Division |
PRI |
| Update Date |
12-OCT-2022 |
| Create Date |
01-AUG-1990 |
| Definition |
RecName: Full=Cytotoxic T-lymphocyte protein 4; AltName: Full=Cytotoxic T-lymphocyte-associated antigen 4; Short=CTLA-4; AltName: CD_antigen=CD152; Flags: Precursor |
| Primary Accession |
P16410 |
| Accession Version |
P16410.3 |
| Other SeqIDs |
sp|P16410.3|CTLA4_HUMAN,gi|27735177 |
| Organism |
Homo sapiens |
| Taxonomy |
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo |
| Comment |
On or before Jul 2, 2013 this sequence version replaced gi:74722235, gi:121940399, gi:74725751, gi:74708169, gi:74726881, gi:87304, gi:231916.; [FUNCTION] Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. {ECO:0000269|PubMed:16551244, ECO:0000269|PubMed:1714933}.; [SUBUNIT] Homodimer; disulfide-linked (PubMed:11279501, PubMed:11279502, Ref.23, PubMed:21156796, PubMed:28484017). Binds to CD80/B7-1 and CD86/B7.2 (PubMed:11279501, PubMed:11279502, PubMed:28484017). Interacts with ICOSLG (PubMed:28484017). {ECO:0000269|PubMed:11279501, ECO:0000269|PubMed:11279502, ECO:0000269|PubMed:21156796, ECO:0000269|PubMed:28484017, ECO:0000269|Ref.23}.; [INTERACTION] P16410; P33681: CD80; NbExp=7; IntAct=EBI-1030991, EBI-1031024; P16410; P42081: CD86; NbExp=3; IntAct=EBI-1030991, EBI-1030956; P16410; Q4LDR2: CTXN3; NbExp=3; IntAct=EBI-1030991, EBI-12019274; P16410; Q13021: MALL; NbExp=3; IntAct=EBI-1030991, EBI-750078; P16410; P27986: PIK3R1; NbExp=3; IntAct=EBI-1030991, EBI-79464; P16410; A2RU14: TMEM218; NbExp=3; IntAct=EBI-1030991, EBI-10173151.; [SUBCELLULAR LOCATION] Cell membrane {ECO:0000269|PubMed:18468488, ECO:0000269|PubMed:28484017}; Single-pass type I membrane protein {ECO:0000269|PubMed:18468488, ECO:0000269|PubMed:28484017}. Note=Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalization.; [ALTERNATIVE PRODUCTS] Event=Alternative splicing; Named isoforms=5; Name=1; IsoId=P16410-1; Sequence=Displayed; Name=2; Synonyms=ss-CTLA-4; IsoId=P16410-2; Sequence=VSP_041284; Name=3; IsoId=P16410-3; Sequence=VSP_041284, VSP_041287; Name=4; IsoId=P16410-4; Sequence=VSP_041285, VSP_041286, VSP_041287; Name=5; IsoId=P16410-5; Sequence=VSP_047238, VSP_047239.; [TISSUE SPECIFICITY] Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation. {ECO:0000269|PubMed:10493833, ECO:0000269|PubMed:16551244, ECO:0000269|PubMed:1713603}.; [PTM] N-glycosylation is important for dimerization. {ECO:0000269|PubMed:11279502, ECO:0000269|PubMed:16002699, ECO:0000269|PubMed:21156796}.; [PTM] Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface. {ECO:0000269|PubMed:10842319, ECO:0000269|PubMed:9175836, ECO:0000269|PubMed:9813138}.; [POLYMORPHISM] Genetic variations in CTLA4 are associated with susceptibility to several autoimmune disorders (PubMed:18595775, PubMed:12724780, PubMed:10189842, PubMed:10924276, PubMed:15138458, PubMed:15657618, PubMed:15688186, PubMed:25329329, PubMed:25213377). They influence responsiveness to hepatitis B virus (HBV) infection [MIM:610424] (PubMed:15452244). {ECO:0000269|PubMed:10189842, ECO:0000269|PubMed:10924276, ECO:0000269|PubMed:12724780, ECO:0000269|PubMed:15138458, ECO:0000269|PubMed:15452244, ECO:0000269|PubMed:15657618, ECO:0000269|PubMed:15688186, ECO:0000269|PubMed:18595775, ECO:0000269|PubMed:25213377, ECO:0000269|PubMed:25329329}.; [DISEASE] Systemic lupus erythematosus (SLE) [MIM:152700]: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. {ECO:0000269|PubMed:15138458, ECO:0000269|PubMed:15688186}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.; [DISEASE] Note=Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism. {ECO:0000269|PubMed:10924276}.; [DISEASE] Diabetes mellitus, insulin-dependent, 12 (IDDM12) [MIM:601388]: A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:9259273}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.; [DISEASE] Celiac disease 3 (CELIAC3) [MIM:609755]: A multifactorial, chronic disorder of the small intestine caused by intolerance to gluten. It is characterized by immune-mediated enteropathy associated with failed intestinal absorption, and malnutrition. In predisposed individuals, the ingestion of gluten-containing food such as wheat and rye induces a flat jejunal mucosa with infiltration of lymphocytes. {ECO:0000269|PubMed:10189842, ECO:0000269|PubMed:15657618}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.; [DISEASE] Autoimmune lymphoproliferative syndrome 5 (ALPS5) [MIM:616100]: An autosomal dominant primary immunodeficiency characterized by severe autoimmunity, infiltration of non-lymphoid organs, such as the intestine, lungs and brain, by hyperactive T cells and B cells, autoimmune cytopenias, and hypogammaglobulinemia in early childhood. {ECO:0000269|PubMed:25213377, ECO:0000269|PubMed:25329329}. Note=The disease is caused by variants affecting the gene represented in this entry.; [PHARMACEUTICAL] Engineered fusion proteins consisting of the extracellular domain of CTLA4 and the IgG Fc region (Ctla4-Ig), inhibit T-cell-dependent antibody responses, and are used as immunosuppressive agents. They are soluble, have an enhanced affinity for B7 ligands and act as a competitive inhibitor of CD28.; [MISCELLANEOUS] The therapeutic antibody Ipilimumab competes for the binding site of the endogenous ligands CD80/B7-1, CD86/B7-2 and ICOSLG.; [WEB RESOURCE] Name=Wikipedia; Note=CLTA-4 entry; URL='https://en.wikipedia.org/wiki/CTLA-4'. |
| Source Db |
UniProtKB: locus CTLA4_HUMAN, accession P16410;; class: standard.; extra accessions:A0N1S0,E9PDH0,O95653,Q0PP65,Q52MC1,Q53TD5,Q5S005,Q8WXJ1,Q96P43,Q9UKN9; created: Aug 1, 1990.; sequence updated: Jan 10, 2003.; annotation updated: Oct 12, 2022.; xrefs: L15006.1, AAB59385.1, M74363.1, AAA52127.1, AF411058.1, AAL40932.1, AY792514.1, AAV66331.1, AY999702.1, AAY00166.1, DQ785106.1, ABG85285.1, AF414120.1, AAL07473.1, DQ357942.1, ABC67470.1, AC010138.6, AAX93176.1, BC074842.2, AAH74842.1, BC074893.2, AAH74893.1, AH002733.2, AAA52773.1, U90273.1, AAD00698.1, AF142144.1, AAF02499.1, S08614, NP_001032720.1, NP_005205.2, 1AH1_A, 1H6E_P, 1I85_C, 1I85_D, 1I8L_C, 1I8L_D, 2X44_D, 3BX7_C, 3OSK_A, 3OSK_B, 5GGV_Y, 5TRU_C, 5TRU_CC, 5XJ3_C, 5XJ3_F, 5XJ3_I, 5XJ3_L, 6RP8_C, 6RP8_CC, 6RPJ_A, 6RPJ_C, 6RPJ_E, 6RPJ_G, 6RQM_A, 6XY2_A, 7CIO_B, 7DV4_A, 7DV4_C, 7DV4_E, 7DV4_G, 7ELX_C, 7ELX_c, 7SU0_C, 7SU0_D, 7SU1_C; xrefs (non-sequence databases): CCDS:CCDS2362.1, CCDS:CCDS42803.1, PDBsum:1AH1, PDBsum:1H6E, PDBsum:1I85, PDBsum:1I8L, PDBsum:2X44, PDBsum:3BX7, PDBsum:3OSK, PDBsum:5GGV, PDBsum:5TRU, PDBsum:5XJ3, PDBsum:6RP8, PDBsum:6RPJ, PDBsum:6RQM, PDBsum:6XY2, PDBsum:7CIO, PDBsum:7DV4, PDBsum:7ELX, PDBsum:7SU0, PDBsum:7SU1, AlphaFoldDB:P16410, SMR:P16410, BioGRID:107875, DIP:DIP-35607N, ELM:P16410, IntAct:P16410, MINT:P16410, STRING:9606.ENSP00000303939, ChEMBL:CHEMBL2364164, DrugBank:DB06186, DrugBank:DB11771, DrugCentral:P16410, GuidetoPHARMACOLOGY:2743, GlyGen:P16410, iPTMnet:P16410, PhosphoSitePlus:P16410, BioMuta:CTLA4, DMDM:27735177, MassIVE:P16410, PaxDb:P16410, PeptideAtlas:P16410, PRIDE:P16410, ABCD:P16410, Antibodypedia:19961, CPTC:P16410, DNASU:1493, Ensembl:ENST00000295854.10, Ensembl:ENSP00000295854.6, Ensembl:ENSG00000163599.18, Ensembl:ENST00000487393.1, Ensembl:ENSP00000497319.1, Ensembl:ENST00000648405.2, Ensembl:ENSP00000497102.1, GeneID:1493, KEGG:hsa:1493, MANE-Select:ENST00000648405.2, UCSC:uc002vak.3, CTD:1493, DisGeNET:1493, GeneCards:CTLA4, HGNC:2505, HPA:ENSG00000163599, MalaCards:CTLA4, MIM:109100, MIM:123890, MIM:152700, MIM:601388, MIM:609755, MIM:610424, MIM:616100, neXtProt:NX_P16410, OpenTargets:ENSG00000163599, Orphanet:391490, Orphanet:436159, Orphanet:2584, Orphanet:900, Orphanet:3162, Orphanet:536, PharmGKB:PA27006, VEuPathDB:HostDB:ENSG00000163599, eggNOG:ENOG502RZVK, GeneTree:ENSGT00530000063873, HOGENOM:CLU_085095_0_0_1, InParanoid:P16410, OMA:WPCSALF, OrthoDB:1222373at2759, PhylomeDB:P16410, TreeFam:TF335679, PathwayCommons:P16410, Reactome:R-HSA-389513, Reactome:R-HSA-8877330, SignaLink:P16410, SIGNOR:P16410, BioGRID-ORCS:1493, EvolutionaryTrace:P16410, GeneWiki:CTLA-4, GenomeRNAi:1493, Pharos:P16410, PRO:PR:P16410, Proteomes:UP000005640, RNAct:P16410, Bgee:ENSG00000163599, Genevisible:P16410, GO:0045334, GO:0009897, GO:0005794, GO:0005887, GO:0048471, GO:0005886, GO:0098636, GO:0002250, GO:0050853, GO:0006974, GO:0006955, GO:0030889, GO:0050777, GO:0045590, GO:0042130, GO:0043065, GO:0050852, Gene3D:2.60.40.10, InterPro:IPR008096, InterPro:IPR040216, InterPro:IPR036179, InterPro:IPR013783, InterPro:IPR003599, InterPro:IPR013106, PANTHER:PTHR11494, PANTHER:PTHR11494:SF8, Pfam:PF07686, PRINTS:PR01720, SMART:SM00409, SMART:SM00406, SUPFAM:SSF48726 |
| Sequence |
maclgfqrhkaqlnlatrtwpctllffllfipvfckamhvaqpavvlassrgiasfvceyaspgkatevrvtvlrqadsqvtevcaatymmgneltflddsictgtssgnqvnltiqglramdtglyickvelmypppyylgigngtqiyvidpepcpdsdfllwilaavssglffysflltavslskmlkkrsplttgvyvkmpptepecekqfqpyfipin |
|
